CORCEPT THERAPEUTICS INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
CORCEPT THERAPEUTICS INC (CORT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 4.90 million shares for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-10.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2016-03-10
- CORCEPT THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2015 was 4.90M shares, a 129.07% increase from fiscal 2014.
- CORCEPT THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2014 was 2.14M shares, a 39.97% decline from fiscal 2013.
- CORCEPT THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2013 was 3.56M shares, a 110.32% increase from fiscal 2012.
- CORCEPT THERAPEUTICS INC share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2012 was 1.70M shares, a 40.00% decline from fiscal 2011.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|
| 2015-12-31 | 4.90M shares 10-K · filed 2016-03-10 |
| 2014-12-31 | 2.14M shares 10-K · filed 2016-03-10 |
| 2013-12-31 | 3.56M shares 10-K · filed 2016-03-10 |
| 2012-12-31 | 1.70M shares 10-K · filed 2015-03-13 |
| 2011-12-31 | 2.83M shares 10-K · filed 2014-03-14 |
| 2010-12-31 | 838.00K shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |